Months before Tennessee attempted to execute Christa Pike, her lawyers warned that a serious medical condition could make the procedure especially painful and dangerous. Their concerns are now drawing renewed attention after she survived the failed execution.
In a court filing submitted on Jan. 8, 2026, Pike’s attorneys said she had a significantly elevated platelet count, a condition known as thrombocytosis. They believed it was likely linked to myeloproliferative disorder, a rare form of blood cancer.
The lawyers argued that her condition could increase the risk of severe pulmonary edema during a lethal injection. This can cause fluid to build up in the lungs and potentially create a terrifying sensation of suffocation.
The filing also highlighted Pike’s history of difficult blood draws and needle insertion. Her attorneys recommended using a butterfly needle, saying it could reduce the risk of unnecessary pain.
But on Sept. 30, the execution attempt went ahead. According to later court filings, prison staff struggled to establish IV lines before administering two doses of pentobarbital. Pike survived and was taken to a hospital, where she remained for 10 days.
Her attorneys had also raised concerns about Tennessee’s execution protocol, including the lack of guaranteed immediate phone access to the courts if complications arose.
Following the failed attempt, Tennessee Gov. Bill Lee suspended the state’s remaining executions for 2026 and ordered an independent investigation.
Pike has since returned to prison, while her lawyers continue to challenge the conditions of her confinement.
The case has renewed questions about whether the medical warnings raised before the execution were adequately addressed.